ClinicalTrials.gg
Not yet recruitingNCT06976021INTROSPECTIONUpdated May 16, 2025

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

A Phase 2 interventional study of Baseline 89-Zr Pembrolizumab Immuno PET-CT and Proteomic assay in Triple Negative Breast Cancer, Uterine Cervical Cancer and Uterine Corpus Cancer, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Phase 2, Interventional, and Diagnostic

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to evaluate the response to four schemes of treatment with novel diagnostic tools - Immuno-PET and proteomics as well as standard imaging (magnetic resonsonce imaging and computed tomography). Two fractionation schedules of radiotherapy will be used. The first will be a common standard of palliative irradiation - 20 Gy delivered in five fractions of 4 Gy (SHORT). The other is called Spatially Fractionated Radiotherapy (SFRT). SFRT is delivered in one fraction of 20 Gy but the dose is diversified inside the tumor to produce areas of high and low doses distributed alternately. This kind of irradiation may be able to stimulate immune response and improve the efficiency of immunotherapy. A drug belonging to the class of immunotherapeutic agents - Pembrolizumab will be added to the treatment scheme in two arms of the study to check that assumption. The response of the target tumor will be evaluated with PET study using Pembrolizumab labeled with zirconium-89 which will show the spatial distribution of immune receptors within the target tumor and other involved sites if there are any. The examination will be repeated after the treatment to evaluate changes in distribution of the immune receptors necessary for the drug to work. Additionally, the researchers will repeatedly test the presence and concentration of a wide panel of proteins in blood to evaluate response to the treatment more precisely.

02

Conditions studied

  • Triple Negative Breast Cancer
  • Uterine Cervical Cancer
  • Uterine Corpus Cancer
  • Malignant Melanoma
  • Clear Cell Renal Cell Carcinoma

Keywords

  • spatially fractionated radiotherapy
  • immunotherapy
  • immuno-PET
  • proteomics
  • signaling pathways
03

In context

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Maria Sklodowska-Curie National Research Institute of Oncology is the lead sponsor of 64 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of clear cell renal cell carcinoma, melanoma, cervical cancer, endometrial cancer or triple negative breast cancer.
  2. Patients nnot eligible for radical treatment with radiotherapy (including stereotactic radiotherapy of the tumor in the potential planned area of irradiation in the study), chemotherapy and palliative immunotherapy in accordance with applicable national standards but who qualify for palliative radiation treatment
  3. General condition according to scale: 60-100
  4. Patients with tumor (index lesion) larger than 5 cm in size that can be irradiated with either SHORT or SFRT technique (presence of other tumors that may be independently treated locally is not an exclusion criterion)
  5. The tumor may be assessed using
  6. Age over 18 years
  7. Granted written, to participate in the research experiment
  8. No to treatment with Pembrolizumab (according to the information provided in the product characteristics).
  9. Expected survival time over 6 months.

Exclusion criteria

Exclusion criteria

  1. Lack of consent to participate in the experiment
  2. to Pembrolizumab according to the product characteristics
  3. Pregnancy and lactation
  4. Inability of the patient to cooperate, including claustrophobia that prevents imaging tests from being performed as planned.
  5. Women of who are unwilling or unable to use an acceptable method of to avoid pregnancy throughout treatment and for 5 months after its completion.
  6. Condition after organ transplantation
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SFRT with immunotherapy

    Diagnostic Test: Baseline 89-Zr Pembrolizumab Immuno PET-CT · Diagnostic Test: Proteomic assay

  • Active comparator
    SHORT with immunotherapy

    Diagnostic Test: Baseline 89-Zr Pembrolizumab Immuno PET-CT · Diagnostic Test: Proteomic assay

  • Experimental
    SFRT

    Diagnostic Test: Baseline 89-Zr Pembrolizumab Immuno PET-CT · Diagnostic Test: Proteomic assay · Diagnostic Test: Follow-up 89-Zr Pembrolizumab Immuno PET-CT

  • Active comparator
    SHORT

    Diagnostic Test: Baseline 89-Zr Pembrolizumab Immuno PET-CT · Diagnostic Test: Proteomic assay · Diagnostic Test: Follow-up 89-Zr Pembrolizumab Immuno PET-CT

Interventions

  • Diagnostic testBaseline 89-Zr Pembrolizumab Immuno PET-CT

    Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89

  • Diagnostic testProteomic assay

    Assessment of the proteomic profile before and periodically after treatment

  • Diagnostic testFollow-up 89-Zr Pembrolizumab Immuno PET-CT

    Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89 after radiotherapy performed in patients who are not treated with immunotherapy

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in expression of PD-1 receptors expressed as a ratio of SUV values

    The expression of PD-1 receptors will be measured with Immuno-PET basing on Zr-89 labeled Pembrolizumab and expressed as the ratio of initial and post-treatment SUV

    Time frame: one year

  2. Change in number of areas with PD-1 receptors expressed as number of lesions

    The localization of regions expressing PD-1 receptors will be identified with Immuno-PET basing on Zr-89 labeled Pembrolizumab and expressed as the number of lesions

    Time frame: one year

  3. Change of proteome expression profile after treatment expressed in NPX (Normalized Protein eXpression) values

    The difference between proteome expression profile before treatment and after the last infusion of Pembrolizumab or after a year in arms without immunotherapy. The Proximity Extension Assay (PEA) technology will be used. Following sequencing, the raw data will be converted to counts, assigning an integer value to each assay-sample combination based on the detected copy numbers. These raw data counts will be converted into NPX values, enabling the identification of protein level changes within different sample sets, and establishing protein signatures.

    Time frame: one year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The individual patient data can be shared upon request. The basic demographic data, type of intervention and outcome measures will be available.

Supporting information: Study protocol, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2029, 54 months later.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 54 months is close to that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2025
First posted
May 16, 2025
StartEst.
Jun 2025
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06976021
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Jun 2025 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
May 16, 2025

Study contacts

Sławomir Blamek, MD, PhD, MBA
Contact
slawomir.blamek@gliwice.nio.gov.pl
+48322788052
Marzena Gawkowska, MD, PhD
Contact
marzena.gawkowska@gliwice.nio.gov.pl
+48322788625
Sławomir Blamek, MD, PhD, MBA
principal investigator · Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion